Archives

Aptahem should have attended the ISICEM conference in Brussels these days, but it has been postponed until September 2020. The abstract that the Aptahem team should have presented at the [...]

BioStock published an article on 16 March 2020 about sepsis and covid-19, which can be read in full below. A new study published in The Lancet shows that sepsis was the most common complication [...]

Aptahem had planned to participate in both BIO Europe Spring and ISICEM during March, but one has been cancelled and the other postponed for six months due to the risk of spreading the Corona [...]

BioStock published an article on 4 March 2020 about Aptahem, which can be read in full below. Aptahem has been listed as a member of the American MTEC, a consortium that cooperates with the U.S. [...]

Aptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The [...]

Aptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s [...]

Aptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of [...]

Aptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the [...]

Aptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are [...]

Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe [...]